Mattias Mattsson

Uppsala, C, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Journal: Experimental hematology & oncology

Published: June 21, 2026

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal: Journal of hematology & oncology

Published: March 15, 2026

Neoehrlichia mikurensis infection associated with lymphoma or mimicking lymphoma in two cohorts of Swedish patients.

Neoehrlichia mikurensis infection associated with lymphoma or mimicking lymphoma in two cohorts of Swedish patients.

Journal: Leukemia & lymphoma

Published: March 04, 2026

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Journal: The Journal of allergy and clinical immunology

Published: December 16, 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: December 08, 2025

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.

Journal: Leukemia

Published: December 20, 2024

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Journal: Blood advances

Published: October 25, 2024

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis.

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis.

Journal: Leukemia

Published: July 20, 2024

Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia.

Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia.

Journal: EJHaem

Published: April 21, 2024

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis.

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis.

Journal: The Journal of molecular diagnostics : JMD

Published: February 13, 2024

Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

Journal: NEJM evidence

Published: February 06, 2024

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.

Journal: Blood advances

Published: January 24, 2024

Showing 1-12 of 56

Last Updated: 09/26/2026